A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...
Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.
† In the COMET trial, there was one death. The drug allocation is still unmasked and we have therefore excluded this death. Combo DMARDs: Combination disease-modifying antirheumatic drugs; MTX: ...
Please provide your email address to receive an email when new articles are posted on . Among patients with rheumatoid arthritis, observed rates of major adverse events from biologic/targeted ...
SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...
SaveHealth reports on psoriatic arthritis medications, detailing options like DMARDs, biologics, and NSAIDs, including their ...
Biologic vs conventional DMARDs may offer cardioprotective benefits among patients with PsA, though an increased risk for infection requires vigilance.
After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback